Proteomic analysis reveals stage‐specific reprogramed metabolism for the primary breast cancer cell lines MGSO‐3 and MACL‐1

Abstract

Breast cancer is the most prevalent cancer in women worldwide. Its molecular subtypes are based on the presence/absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). MACL-1 and MGSO-3 are cell lines derived from primary tumor sites of patients diagnosed with luminal A subtype carcinoma (ER+/PR+/HER2−) and ductal carcinoma in situ (ER−/PR−/HER2+), respectively. However, these cell lines lost the expression of these markers over cell culturing, and both have triple-negative phenotypes (ER−/PR−/HER2−), which has the poorest prognosis. Here, we sought to study the proteome signature of MGSO-3 and MACL-1, comparing them with the epithelial cell line MCF-10A and the well-established metastatic-derived breast cancer cell line MDA-MB-231. Our results showed that proteins associated with the tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OXPHOS) were upregulated in MGSO-3 and MACL-1 cells. These cell lines also showed upregulation of pro-apoptotic proteins when compared with MDA-MB-231. The molecular differences highlighted in this study may clarify the molecular basis behind cancer cells functioning and may reveal novel signatures across the breast cancer cell models.

Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype

“…In order to assess the expression profile of the DCIS proteome, as well as the expression profile of invasive biomarkers, isobaric tag for relative and absolute quantitation (iTRAQ) technology coupled with nLC–MS/MS analysis has been successfully used [ 53 ]. Based on the proteomic signature across the BC cell models, the LC–MS/MS technique revealed a stage-specific reprogrammed metabolism [ 54 ]. HER2 overexpression has been reported in the case of DCIS tumors that progress to IDC [ 55 ].…”